Comparison and evaluation of cardiac biomarkers in patients with intermittent claudication: results from the CAVASIC study.

Barbara Kollerits, Gisela Sturm, Claudia Lamina, Angelika Hammerer-Lercher, Barbara Rantner, Marietta Stadler, Tim Ziera, Joachim Struck, Peter Klein-Weigel, Gustav Fraedrich, Florian Kronenberg

Division of Genetic Epidemiology, Department of Medical Genetics, Molecular and Clinical Pharmacology, Innsbruck Medical University, Innsbruck, Austria.

Clinical chemistry 2013 Apr

filter terms:

Plasma concentrations of the peptides midregional proadrenomedullin (MR-proADM), midregional proatrial natriuretic peptide (MR-proANP), and C-terminal endothelin-1 precursor fragment (CT-proET-1) are increased in various cardiovascular conditions. However, there is limited information about the association and comparative performance of these peptides in peripheral arterial disease (PAD). The associations of MR-proADM, MR-proANP, and CT-proET-1 plasma concentrations with symptomatic PAD were investigated in the CAVASIC (Cardiovascular Disease in Intermittent Claudication) Study. Study participants were a male cohort of 238 patients with a diagnosis of intermittent claudication (IC) and 245 age- and diabetes-matched controls. Results were compared to those for N-terminal pro-B-type natriuretic peptide (NT-proBNP). Each increase of MR-proADM, MR-proANP, and CT-proET-1 by 1 SD was significantly associated with symptomatic PAD: odds ratio (OR) = 1.78 (95% CI, 1.41-2.25, P < 0.001), OR = 1.32 (95% CI, 1.06-1.66, P = 0.014), and OR = 1.80 (95% CI, 1.43-2.28, P < 0.001), respectively. The association remained significant for all 3 markers after additional adjustment for log C-reactive protein, serum creatinine, HDL cholesterol, and current smoking. When one adjusts for log NT-proBNP and excluding individuals with prevalent cardiovascular disease, MR-proADM and CT-proET-1 still predicted symptomatic PAD. Extended adjustment models including MR-proADM or CT-proET-1 showed significantly improved model fits compared to models including classical cardiac risk factors or NT-proBNP and led to significant reclassification (P < 0.05). This study in a male coho rt of patients with IC and age- and diabetes-matched controls indicates a significant association of high MR-proADM, MR-proANP, and CT-proET-1 concentrations with PAD. MR-proADM and CT-proET-1 provide additive information in comparison to NT-proBNP. Moreover, MR-proADM and CT-proET-1 significantly predict PAD in those patients and controls free from prevalent CVD. © 2012 American Association for Clinical Chemistry

Citation

Barbara Kollerits, Gisela Sturm, Claudia Lamina, Angelika Hammerer-Lercher, Barbara Rantner, Marietta Stadler, Tim Ziera, Joachim Struck, Peter Klein-Weigel, Gustav Fraedrich, Florian Kronenberg. Comparison and evaluation of cardiac biomarkers in patients with intermittent claudication: results from the CAVASIC study. Clinical chemistry. 2013 Apr;59(4):692-702